| Gene symbol | KRAS | Synonyms | C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | KRAS proto-oncogene, GTPase | ||||
| GTO ID | GTC2016 |
| Trial ID | NCT03745326 |
| Disease | Stomach Cancer | Pancreatic Cancer | Rectal Cancer | Gastrointestinal Allergy | Colon Cancer |
| Altered gene | KRAS |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | KRAS G12D TCR-T cells |
| HLA | HLA-A*11:01 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients |
| Year | 2018 |
| Country | United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | 190017|19-C-0016 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||
|
|||||||||